Anatara Lifesciences Ltd
Anatara Lifesciences Ltd is an Australia-based life sciences company.
The business
Anatara Lifesciences Ltd is an Australia-based life sciences company. The Company is engaged in developing evidence-based solutions for gastrointestinal diseases in humans and animals. Its products include Gastrointestinal ReProgramming (GaRP), Detach, BONIFF, and ANR-pf. Its GaRP Product is a microbiome-targeted multi-component complementary medicine, which is designed to address the primary underlying factors associated with chronic gastrointestinal conditions, such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Detach is a non-antibiotic approach to aid in the control of diarrheal disease known as scour, which is developed using bromelain. BONIFF is a revised formulation which is applied to dry feed for piglets after weaning, reducing labor input, and simplifying the entire process. ANR-pf is an enriched formulation for poultry in water, designed to allow the full delivery of key additives in a quick and flexible dosing method.
Small Caps Research
No research on Anatara Lifesciences Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise ANR based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Anatara Lifesciences on track with recruitment for Stage 2 of GaRP IBS trial
Anatara Lifesciences (ASX: ANR) has reported that recruitment for Stage 2 of its pivotal GaRP (Gastrointestinal ReProgramming) trial for the treatment of irritable bowel syndrome (IBS) is proceeding well and remains on budget. The company has also confirmed an extension to the recruitment timeline through to August. Stage 2 of the GaRP trial follows the […]
Anatara Lifesciences’ Stage 2 GaRP trial for IBS treatment gains momentum
Recruitment is advancing for Stage 2 of Anatara Lifesciences’ (ASX: ANR) pivotal gastrointestinal reprogramming (GaRP) trial to treat irritable bowel syndrome (IBS). The five trial sites in Melbourne, Sydney and Brisbane have received more than 500 expressions of interest and have completed the standard screening processes consistent with Stage 1. Thirteen participants have been enrolled […]
Anatara Lifesciences embarks on Stage 2 of GaRP trial for treatment of irritable bowel syndrome
Anatara Lifesciences (ASX: ANR) has initiated Stage 2 of a Phase II gastrointestinal re-programming (GaRP) trial to treat patients with irritable bowel syndrome (IBS). The milestone follows “highly encouraging” findings from Stage 1 of the trial, whereby 61 intent-to-treat participants were given low- and high-dose regimens of the medication. Stage 1 of the trial was […]
Market wrap: share market searching for a new theory as interest rate cuts evaporate
Investors are scrambling around looking for a new investment thesis after the long-awaited prospect of global official interest rate cuts continued to fade out of view. A combination of stubbornly resurgent inflation in the United States, the potentially worsening war in the Middle East and the prospect of a US election campaign all contributed to […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.